KalVista Pharmaceuticals Reports Fiscal First Quarter Results

Published: Sep 14, 2017

– Portfolio of Oral Plasma Kallikrein Inhibitors for Treatment of Hereditary Angioedema Continues to Advance –

– Intravitreal Diabetic Macular Edema Candidate KVD001 Remains on Track for Phase 2 in 2017 –

CAMBRIDGE, Mass.--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today reported operational and financial results for the fiscal first quarter ended July 31, 2017.

“We continue to make progress with our portfolio of oral plasma kallikrein inhibitors in pursuit of our goal of a best-in-class oral therapy for hereditary angioedema,” said Andrew Crockett, Chief Executive Officer of KalVista. “We are completing the first-in-human trial of KVD818 and plan to evaluate final data and determine future development plans as we continue to advance our additional molecules. KVD900 remains on track to be our next candidate to enter clinical testing, with a regulatory filing before the end of 2017, and there will be at least one additional candidate entering the clinic in 2018. We also continue preparations for the Phase 2 clinical trial for our diabetic macular edema program candidate KVD001, which will initiate this year.”

First Quarter and Recent Business Highlights:

  • Edward Feener, Ph.D., gave a talk at the International Society on Thrombosis and Haemostasis (ISTH) Congress entitled “Contact System in Diabetic Retinopathy,” on July 9, 2017 in Berlin, Germany.

Fiscal First Quarter Financial Results:

Back to news